Navigation Links
Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
Date:9/5/2012

SUNNYVALE, Calif., Sept. 5, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results and recent developments for its fiscal year and fourth quarter ended June 30, 2012.

Financial Results for Fiscal Year and Fourth Quarter Ended June 30, 2012The non-GAAP (Generally Accepted Accounting Principles) net income reported for the fiscal year ended June 30, 2012 was $21.9 million, or $0.32 and $0.30 per basic and diluted earnings per share, respectively. This compares with a non-GAAP net loss of $28.0 million, or $0.47 loss per share, for the fiscal year ended June 30, 2011. For the quarter ended June 30, 2012, the non-GAAP net loss was $15.1 million, or $0.22 loss per share, which compares with a non-GAAP net loss of $9.1 million, or $0.15 loss per share for the 2011 quarter. See "Use of Non-GAAP Financial Measures" below for a description of our Non-GAAP measures. Reconciliation between certain GAAP and non-GAAP measures is provided at the end of this press release.

The GAAP net income for the fiscal year ended June 30, 2012 was $12.0 million, or $0.17 per basic and diluted earnings per share.  This compares with a GAAP net loss of $35.2 million, or $0.59 loss per share for the year ended June 30, 2011.  For the quarter ended June 30, 2012, the GAAP net loss was $16.9 million, or $0.24 loss per share. This compares with a GAAP net loss of $11.0 million, or $0.18 loss per share for the fiscal quarter ended June 30, 2011.

Revenue for the fiscal year ended June 30, 2012 was $82.0 million, compared to $8.2 million for the fiscal year ended June 30, 2011, an increase of $73.8 million. Revenue for the quarter ended June 30, 2012 was $2.1 million, compared to $1.4 million for the quarter ended June 30, 2011, an increase of $0.7 million.

At June 30, 2012, the Company had cash, cash equivalents and marketable securit
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
7. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
8. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
9. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
10. Luminex Corporation Reports First Quarter 2012 Results
11. Hospira Reports First-Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 An aggressive campaign ... cut the rate of infection with a dangerous drug-resistant ... Clostridium difficile, or C.diff, is a bacterium ... inflammation of the colon. A recent article in the ... difficile Infection in the United States ...
(Date:2/27/2015)... February 27, 2015 Report Details ... showing you trends, R&D progress, and predicted revenues ,Where ... What are the commercial prospects for this market and ... revenues and other trends to 2025, discussing data, opportunities ... you assess regenerative medicine : cell-based therapies that ...
(Date:2/27/2015)... , Feb. 27, 2015  In recognition of Rare ... to the global bleeding disorders community, CSL Behring ... international units (IUs) of protein therapies to the World ... profit organization which has worked to improve the lives ... The donation supports the WFH,s Global Alliance for Progress ...
Breaking Medicine Technology:Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3
... First-Ever Trial to Evaluate Whether Olmesartan Medoxomil Prevents Onset of ... May 8 Blinded one-year blood pressure (BP) reduction data ... andomized O lmesartan A nd D iabetes ... today at the American Society of Hypertension (ASH) Twenty-Fourth Annual ...
... 24-Hour Ambulatory BP MeasuresPARSIPPANY, N.J., May 8 Daiichi ... American Society of Hypertension, Inc. (ASH) Twenty-Fourth Annual Scientific ... the AZ OR(R) T rial E ... AZTEC ) demonstrated that a stepwise amlodipine and olmesartan ...
Cached Medicine Technology:Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results 2Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results 3Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results 4Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results 5Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results 6Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results 7New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 2New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 3New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 4New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 5New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 6New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 7New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 8New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 9
(Date:3/1/2015)... March 01, 2015 Ticket Down is a ... Chicago at Soldier Field. Deadheads have been anxiously ... January. , Grateful Dead was formed 50 years ago back ... together as one until the untimely death of Jerry Garcia ... different genres including blues, reggae, rock, bluegrass, folk, space rock ...
(Date:3/1/2015)... ERISAPros is pleased to announce ... the professional staff of its Compliance Department. , Evelyn ... State University-Mortiz College of Law. Prior to joining ERISAPros, ... several Fortune 500 companies as well as several privately ... Her experiences range from benefit plan design, vendor management, ...
(Date:3/1/2015)... 2015 CrossFit Attollo is a CrossFit gym ... a special discount to new members. Now through the ... three month contract will receive their fourth month half off. ... members $440. The three month contract is only $264, ... the fourth month comes in at only $55. The special ...
(Date:2/28/2015)... 2015 Heart diseases are on the ... of urban adult population and 5 percent of rural ... and 20-30 percent of them require specialized investigation and ... coronary vascular diseases (CVD). , A division of Indian ... research report titled “Indian Coronary Stent Market Forecast to ...
(Date:2/28/2015)... With their commitment to achieving physical ... additional exercise to their already robust library of oblique ... commonly known as, is often performed on a stationary ... in a relatively safe manner and can be performed ... full description of “Rope Pulls” is located in the ...
Breaking Medicine News(10 mins):Health News:Grateful Dead Tickets at Soldier Field in Chicago: Ticket Down Slashes Grateful Dead Ticket Prices in Chicago at Soldier Field for 4th of July Weekend Celebration 2Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3
... last 25 years, in New York, there has been a ... has increased. Researchers at the University of Texas, have analysed ... between 1981 and 1999.// They find there has been a ... 2.0 cases per 150,000 population to 12.2 per 100,000. For ...
... some valuable advice on how to make sure your vitamin ... and teeth, and helps prevent osteoporosis and any bone related ... vitamin D.// Just10 to 15 minutes of natural sunlight three ... factors can reduce sunlight exposure, such as windows, sunscreen, smog ...
... at the critical care centre felt that, everyone should ... response to infection. Sepsis occurs when the body over-reacts ... is associated with cancer but it can attack anyone.// ... pancreatic and prostate cancer together, and is the leading ...
... with transplanted hearts from female donors, the proof is the ... at least somewhat by recruiting cells from elsewhere in the ... or dead, they could not be replaced or repaired by ... is found only in men, researchers determined that the female ...
... many people with firm spiritual beliefs find it easier to ... relatives and friends of patients attending a hospice for terminal ... strong spiritual beliefs helped these people cope when their loved ... belief reported steady progress in coming to terms with their ...
... oxygen therapy at home reduces hospitalisation in those with lung ... the effects of oxygen on 200 patients with smoker's lungs// ... was begun in an outpatient clinic, then continued at home. ... a day, proved to be beneficial. The patients had a ...
Cached Medicine News:
The Auto Suture™ Woodford Spike™ Trocar and Cannula is a sterile, single-use device designed for primary punctures during laparoscopy. Dexide refers to a separate offering of trocars from...
... line of Surgical Access ...unlike any trocar ... trocar system is actually four systems in ... flexible and clinically adaptive to all of ... disposability and bladed or dilating tip styles, ...
Thoracoscopy Cannula, reusable, hook electrode, two lengths, mini or basic kit....
... we believe that the trocar should be ... instrument precision and speeding the process. So ... trocar that meets the needs of the ... Xcel - The only trocar that affords ...
Medicine Products: